Histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Comparison of recent WHO classification published 2017 and classification of Histiocyte Society published 2016

Czech version

Authors: Zdeněk Král ¹; Zdeněk Adam ¹; Marta Ježová ²; Luděk Pour ¹; Marta Krejčí ¹
Authors‘ workplace: Interní hematoonkologická klinika LF MU a FN Brno, pracoviště Bohunice ¹; Ústav patologie LF MU a FN Brno, pracoviště Bohunice ²
Published in: Vnitř Lék 2020; 66(6): 19-27
Category:

Overview

The histiocytoses are rare disorders characterized by the accumulation of cells thought to be derived from dendritic cells or macrophages. Their clinical behaviour ranges from mild to disseminated and, sometimes, life-threatening forms. The incidence of this diseases is much smaller, then the incidence of diseases derived from lymphocytic or myeloid lineage. Langerhans cell histiocytosis is most frequent disease from this group. The last version of WHO classification from 2017 and last version of classification published by Histiocyte Society is summarised in this paper.

Keywords:

Langerhans cell histiocytosis – Erdheim Chester disease – sarcomas from dendritic cells – Rosai-Dorfman disease – haemophagocytic histiocytosis

Sources

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of the tumours of Haematopoietic and lymphoid diseases. Revised 4th edition, Lyon 2017, 585 s.

2. Emile JF, Abla O, Fraitag S, et al. Histiocyte Society. Revised classification of histiocytoses and neoplasms of the macrophage- dendritic cell lineages. Blood 2016; 127: 2672–2681.

3. Chen M, Ding C, Lu T, et al. Langerhans cell histiocytosis and Erdheim -Chester disease overlap syndrome with bone marrow involvement and type 2 diabetes mellitus. Ann Hematol 2018; 97: 189–192.

4. Novosad O, Skrypets T, Pastushenko Y, et al. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis. Klinická onkol 2018; v tisku.

5. Tzankov A, Kremer M, Leguit R, et al. Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016. Ann Hematol 2018; 97: 2117–2128.

6. Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-Mutant Erdheim- Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology -Independent, Phase 2, Open -label VE -BASKET Study. JAMA Oncol 2018; 4: 384–388.

7. Girschikofsky M, Arico M, Castillo D, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro- Histio-Net. Orphanet J Rare Dis 2013; 8: 72.

8. Haupt R, Minkov M, Astigarraga I, et al. Euro Histio Network. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work- up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer 2013; 60: 175–184.

9. Kolenová A, Bubanská E, Špotová A, et al. Cielená liečba závažnej multisystémovej histiocytózy z Langerhansových buniek. Pediatr Prax 2018; 19: 27–31.

10. Nakamine H, Yamakawa M, Yoshino T, et al. Langerhans Cell Histiocytosis and Langerhans Cell Sarcoma: Current Understanding and Differential Diagnosis. J Clin Exp Hematop 2016; 56: 109–118.

11. Xu XL, Bu WB, Zong WK, et al. Indeterminate cell histiocytosis: a case series and review of the literature. Eur J Dermatol 2017; 27: 559–561.

12. Rezk SA, Spagnolo DV, Brynes RK, et al. Indeterminate cell tumor: a rare dendritic neoplasm. Am J Surg Pathol 2008; 32: 1868–1876.

13. Cohen- Aubart F, Emile JF, Carrat F, et al. Phenotypes and survival in Erdheim- Chester disease: Results from a 165-patient cohort. Am J Hematol 2018; doi: 10.1002/ajh.25055.

14. Suzuki H, Wanibuchi M, Komatsu K, et al. Erdheim- Chester Disease Involving the Central Nervous System with the Unique Appearance of a Coated Vertebral Artery. NMC Case Rep J 2016; 3: 125–128.

15. Papo M, Diamond EL, Cohen- Aubart F, et al. High prevalence of myeloid neoplasms in adults with non -Langerhans cell histiocytosis. Blood 2017; 130: 1007–1013.

16. Cao XX, Niu N, Sun J, et al. Clinical and positron emission tomography responses to long -term high -dose interferon -α treatment among patients with Erdheim -Chester disease. Orphanet J Rare Dis 2019; 14: 11.

17. Goyal G, Shah MV, Call TG, et al. Efficacy of biological agents in the treatment of Erdheim-Chester disease. Br J Haematol 2017; doi:10.1111/bjh.14997.

18. Oneal PA, Kwitkowski V, Luo L, et al. FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim- Chester Disease with the BRAFV600 Mutation. Oncologist 2018; 23: 1520–1524.

19. Cohen Aubart F, Emile JF, et al. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow- up after interruption (the LOVE study). Blood 2017; 130: 1377–1380.

20. Tamura S, Kawamoto K, Miyoshi H, et al. Cladribine treatment for Erdheim- Chester disease involving the central nervous system and concomitant polycythemia vera: A case report. J Clin Exp Hematop 2018; 58: 161–165.

21. Adam Z, Szturz P, Pour L, et al. Kladribin je vysoce účinný v léčbě histiocytózy z Langerhanosových buněk a vzácných chorob ze skupiny juvelního xantogranulomu. Vnitř Lék 2012; 58: 455–465.

22. Franconieri F, Deshayes S, de Boysson H et al. Superior efficacy and similar safety of double dose anakinra in Erdheim -Chester disease after single dose treatment. Oncoimmunology 2018; 7: e1450712.

23. Hao X, Feng R, Bi Y, et al. Dramatic efficacy of dabrafenib in Erdheim- Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis. J Neurosurg Pediatr 2018; 23: 48–53.

24. Al Bayati A, Plate T, Al Bayati M, et al. Dabrafenib and Trametinib Treatment for Erdheim -Chester Disease With Brain Stem Involvement. Mayo Clin Proc Innov Qual Outcomes 2018; 2: 303–308.

25. Luder CM, Nordmann TM, et al. Histiocytosis - cutaneous manifestations of hematopoietic neoplasm and non -neoplastic histiocytic proliferations. J Eur Acad Dermatol Venereol 2018; doi: 10.1111/jdv.14794.

26. Mahendran P, Wee J, Chong H, et al. Necrobiotic xanthogranuloma treated with lenalidomide. Clin Exp Dermatol 2018; 43: 345–347.

27. Sagiv O, Thakar SD, Morrell G, et al. Rituximab Monotherapy Is Effective in Treating Orbital Necrobiotic Xanthogranuloma. Ophthal Plast Reconstr Surg 2018; 34: e24–e27.

28. Techavichit P, Sosothikul D, Chaichana T, et al. BRAF V600E mutation in pediatric intracranial and cranial juvenile xanthogranuloma. Hum Pathol 2017; 69: 118–122.

29. Fölster- Holst R. Severe systemic juvenile xanthogranuloma is an indication for systemic therapy. Br J Dermatol 2017; 176: 302–304.

30. Klingner M, Hansel G, Schönlebe J, et al. Disseminated necrobiotic xanthogranuloma. Hautarzt 2016; 67: 902–906.

31. Honda Y, Nakamizo S, Dainichi T, et al. Adult -onset asthma and periocular xanthogranuloma associated with IgG4-related disease with infiltration of regulatory T cells. J Eur Acad Dermatol Venereol 2017; 31: e124–e125.

32. Miguel D, Lukacs J, Illing T, et al. Treatment of necrobiotic xanthogranuloma - a systematic review. J Eur Acad Dermatol Venereol 2017; 31: 221–235.

33. Maintz L, Wenzel J, Irnich M, et al. Successful treatment of systemic juvenile xanthogranulomatosis with cytarabine and 2-chlorodeoxyadenosine: case report and review of the literature. Br J Dermatol 2017; 176: 481–487.

34. Higgins LS, Go RS, Dingli D, et al. Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. Clin Lymphoma Myeloma Leuk 2016; 16: 447–452.

35. Hilal T, DiCaudo DJ, Connolly SM et al. Necrobiotic xanthogranuloma: a 30-year single-center experience. Ann Hematol 2018; 97: 1471–1479.

36. Sagiv O, Thakar SD, Morrell G, et al. Rituximab Monotherapy Is Effective in Treating Orbital Necrobiotic Xanthogranuloma. Ophthalmic Plast Reconstr Surg 2018; 34: e24–e27.

37. Jacobsen E, Shanmugam V, Jagannathan J. Rosai- Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib. N Engl J Med 2017; 377: 2398–2399.

38. Matter MS, Bihl M, Juskevicius D. Is Rosai- Dorfman disease a reactve process? Detection of a MAP2K1 L115V mutation in a case of Rosai -Dorfman disease. Virchows Arch 2017; 471: 545–547.

39. Hasegawa M, Sakai F, Okabayashi A, et al. Rosai -Dorfman Disease of the Lung Overlapping with IgG4-related Disease: The Difficulty in Its Differential Diagnosis. Intern Med 2017; 56: 937–941.

40. Ghawas MS, Ng T, Chen LYC. Confirmed Efficacy of Lenalidomide and Dexamethasone in Unresectable Cutaneous Facial Rosai -Dorfman -Destombes Disease Mayo Clin Proc Innov Qual Outcomes 2019; 3: 94–96.

41. Geller S, Busam K, Hamlin PA et al. Treatment of Rosai- Dorfman disease with oral bexarotene: a case series. J Dermatolog Treat 2018; doi: 10.1080/09546634.2018.1528001.

42. Averitt AW, Heym K, Akers L, et al. Sinus Histiocytosis With Massive Lymphadenopathy (Rosai Dorfman Disease): Diagnostic and Treatment Modalities for this Rare Entity Revisited. J Pediatr Hematol Oncol 2018; 40: e198–e202.

43. Huhn D. Therapy of malignant histiocytosis. Haematol Blood Transfus 1981; 27: 211–216.

44. Kommalapati A, Tella SH, Durkin M, et al. Histiocytic sarcoma: a population -based analysis of incidence, demographic disparities, and long- term outcomes. Blood 2018; 131: 265–268.

45. Kommalapati A, Tella SH, Durkin M, et al. Histiocytic sarcoma: a population- based analysis of incidence, demographic disparities, and long- term outcomes. Blood 2018; 131: 265–268.

46. Broadwater DR, Conant JL, Czuchlewski DR, et al. Clinicopathologic Features and Clinical Outcome Differences in De Novo Versus Secondary Histiocytic Sarcomas: A Multi-institutional Experience and Review of the Literature. Clin Lymphoma Myeloma Leuk 2018; 18: e427–e435.

47. Voruz S, Cairoli A, Naveiras O, et al. Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma. Haematologica 2018; 103: e39–e41.

48. Iwabuchi H, Kawashima H, Umezu H, et al. Successful treatment of histiocytic sarcoma with cladribine and high- dose cytosine arabinoside in a child. Int J Hematol 2017; 106: 299–303.

49. Gounder MM, Solit DB, Tap WD. Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation. N Engl J Med 2018; 378: 1945–1947.

50. Chen T, Gopal P. Follicular Dendritic Cell Sarcoma. Arch Pathol Lab Med 2017; 141: 596–599.

51. Facchetti F, Lorenzi L. Follicular dendritic cells and related sarcoma. Semin Diagn Pathol 2016; 33: 262–276.

52. Jain P, Milgrom SA, Patel KP, et al. Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. Br J Haematol 2017; 178: 403–412.

53. Sasaki M, Izumi H, Yokoyama T, et al. Follicular dendritic cell sarcoma treated with a variety of chemotherapy. Hematol Oncol 2017; 35: 905–908.

54. Purkait S, Mallick S, Joshi PP, et al. Retroperitoneal and mediastinal follicular dendritic cell sarcoma: report of 3 cases with review of literature. Hematol Oncol 2017; 35: 374–379.

55. Ninkovic S, Cole- Sinclair MF. Interdigitating dendritic cell sarcoma: diagnostic pitfalls, treatment challenges and role of transdifferentation in pathogenesis. Pathology 2017; 49: 643–646.

56. Nguyen CM, Cassarino D. Primary Cutaneous Interdigitating Dendritic Cell Sarcoma: A Case Report and Review of the Literature. Am J Dermatopathol 2016; 38: 628–631.

57. Di Liso E, Pennelli N, Lodovichetti G, et al. Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature. Cancer Biol Ther 2015; 16: 1128–1135.

58. Minoia F, Bovis F, Davì S, et al. Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. J Pediatr 2017; 189: 72–78.e3.

59. Lerkvaleekul B, Vilaiyuk S. Macrophage activation syndrome: early diagnosis is key. Open Access Rheumatol 2018; 10: 117–128.

60. Otrock ZK, Daver N, Kantarjian HM, et al. Diagnostic Challenges of Hemophagocytic Lymphohistiocytosis. Clin Lymphoma Myeloma Leuk 2017; 17: S105–S110.

61. Henter JI, Horne A, Aricó M et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48: 124–131.

62. Šrámek J, Karvunidis T, Lysák D, et al. Hemofagocytární lymfohistiocytóza u dospělých - review a kazuistika. Vnitř Lék 2018; 64: 300–307

63. La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019; doi: 10.1182/blood.2018894618.

64. Bergsten E, Horne A, Aricó M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long- term results of the cooperative HLH-2004 study. Blood 2017; 130: 2728–2738.

65. Risma KA, Marsh RA. Hemophagocytic Lymphohistiocytosis: Clinical Presentations and Diagnosis. J Allergy Clin Immunol Pract 2019; 7: 824–832.

66. Daver N, McClain K, Allen CE, et al. A consensus review on malignancy- associated hemophagocytic lymphohistiocytosis in adults. Cancer 2017; 123: 3229–3240.

67. Zandvakili I, Conboy CB, Ayed AO, et al. Ruxolitinib as first- line treatment in secondary hemophagocytic lymphohistiocytosis: A second experience. Am J Hematol 2018; doi: 10.1002/ajh.25063.

68. Cuglievan B, Miranda RN. Kikuchi -Fujimoto disease. Blood 2017; 129: 917–918.